SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as the board investigates CEO Jensen Huangs acknowledged relationship with a businesswoman whom U.S. intelligence reportedly suspects of ties to China; the espionage allegations remain unproven. Traders are divided between viewing the scrutiny and possible leadership fallout as serious risks and treating the controversy as an overreaction that does not change Nvidias AI-chip business.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs pending decision on Capricors deramiocel for Duchenne muscular dystrophy, particularly whether HOPE-3 upper-limb results support approval. Many traders cite the trial data and physician support as reasons for optimism, while others warn that FDA concerns over the analyses leave rejection risk unresolved; short-squeeze talk is also common.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A weaker-than-expected Q3 report and slower-than-hoped ANKTIVA sales drove a sharp selloff, with traders debating whether limited adoption, competition, and BCG supply constraints could pressure growth and increase dilution risk. Some investors view the positive BCG-naive trial result and expanded approvals as support for the longer-term outlook, but remain split on whether those developments can translate into stronger sales.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are drawing attention amid a sharp run-up into quarterly earnings, with traders speculating about a strong report and a possible short squeeze. Optimism is tempered by concerns about the companys recent performance and fears that the stock could reverse after results, as it has in prior earnings periods.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results and CEO Brad Jacobs bullish conference-call comments are driving attention, with traders encouraged by reported growth and the companys outlook. Bulls see room for a rebound or short-covering, while skeptics remain cautious after the stocks prolonged decline and amid housing-market and interest-rate concerns.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics BRIUMVI-driven quarterly sales beat and raised full-year outlook are the main focus, with traders also watching for Phase 3 data on a self-administered version. Despite the upbeat report and call, shares fell, prompting debate over sell-the-news pressure and speculation about short selling.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Q3 earnings and guidance dominate discussion, with traders weighing the Lilly obesity-drug deals growth potential against margin pressure from branded GLP-1 sales. Some speculate the selloff reflects leaked results, but that claim is unconfirmed.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation beat quarterly expectations and raised its full-year earnings outlook again, prompting traders to focus on its earnings momentum and exposure to rising AI and data-center power demand. Many praised the report, while others questioned the muted share reaction and whether the move would hold.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics CTX310 Phase 1b data is drawing attention, with traders focusing on reported reductions in ANGPTL3 and triglycerides and the therapys tolerability. The response is cautiously positive, but some question the small patient sample and limited follow-up, while others are frustrated that favorable data has not translated into stronger share-price movement.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Positive Phase 3 ECLIPSE-1 results for Virs hepatitis delta treatment, alongside durable viral suppression in extended SOLSTICE data, are driving attention; traders are bullish on the results but debate whether the news is already priced in and whether Vir should remain independent or attract a buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dark pool check on $CVS: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. 
 
Look up any stock&#39;s options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&amp;sym=CVS&amp;utm_source=stocktwits&amp;utm_medium=social&amp;utm_campaign=trial&amp;utm_content=CVS 
 
Read the full article for the full details: 
https://globaltradersacademy.com/articles/dark-pool-activity-what-big-money-did-in-cvs-health-cvs-off-the-exchanges?utm_source=stocktwits&amp;utm_medium=social

Off-exchange trading in CVS Health (CVS) ran above its normal pace. See how many shares big money moved in the dark, and what the options flow says beside it.

Global Traders Academy

Dark Pool Activity: What Big Money Did in CVS Health (CVS) Off the Exchanges

The GTA Terminal: stock scanners, unusual options flow and gamma, Congress, insider and institutional trades, proprietary Underdog picks, macro, pattern scans and price alerts. Try Pro free for 7 days.

GTA Terminal · Trade with the smart money on your side

StockTwits Web

CVS Health Corp

: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. 
 
Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: 

 
 
Read the full article for the full details: 
